256 related articles for article (PubMed ID: 37804781)
1. Propensity-score matched analysis of patent foramen ovale closure in real-world study cohort with cryptogenic ischemic stroke.
Low CE; Teo YN; Teo YH; Lim ICZ; Rana S; Lee YQ; Chen X; Fang JT; Lam HH; Ong K; Yang J; Kuntjoro I; Low TT; Lee EC; Sharma VK; Yeo LL; Sia CH; Tan BY; Lim Y
J Stroke Cerebrovasc Dis; 2023 Dec; 32(12):107407. PubMed ID: 37804781
[TBL] [Abstract][Full Text] [Related]
2. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
3. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials.
Kent DM; Saver JL; Ruthazer R; Furlan AJ; Reisman M; Carroll JD; Smalling RW; Jüni P; Mattle HP; Meier B; Thaler DE
Stroke; 2020 Oct; 51(10):3119-3123. PubMed ID: 32921262
[TBL] [Abstract][Full Text] [Related]
4. Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events.
Alperi A; Guedeney P; Horlick E; Nombela-Franco L; Freixa X; Pascual I; Mesnier J; Houde C; Abrahamyan L; Montalescot G; Rodés-Cabau J
Circ Cardiovasc Interv; 2022 Jul; 15(7):e011652. PubMed ID: 35735021
[TBL] [Abstract][Full Text] [Related]
5. Propensity Score-Based Analysis of Percutaneous Closure Versus Medical Therapy in Patients With Cryptogenic Stroke and Patent Foramen Ovale: The IPSYS Registry (Italian Project on Stroke in Young Adults).
Pezzini A; Grassi M; Lodigiani C; Patella R; Gandolfo C; Zini A; DeLodovici ML; Paciaroni M; Del Sette M; Toriello A; Musolino R; Calabrò RS; Bovi P; Adami A; Silvestrelli G; Sessa M; Cavallini A; Marcheselli S; Marco Bonifati D; Checcarelli N; Tancredi L; Chiti A; Del Zotto E; Tomelleri G; Spalloni A; Giorli E; Costa P; Giacalone G; Ferrazzi P; Poli L; Morotti A; Piras V; Rasura M; Simone AM; Gamba M; Cerrato P; Zedde ML; Micieli G; Melis M; Massucco D; Guido D; De Giuli V; Bonaiti S; D'Amore C; La Starza S; Iacoviello L; Padovani A;
Circ Cardiovasc Interv; 2016 Sep; 9(9):. PubMed ID: 27582111
[TBL] [Abstract][Full Text] [Related]
6. Sex Differences in Patients With Cryptogenic Cerebrovascular Events Undergoing Transcatheter Closure of Patent Foramen Ovale.
Farjat-Pasos JI; Guedeney P; Houde C; Alperi A; Robichaud M; Côté M; Montalescot G; Rodés-Cabau J
J Am Heart Assoc; 2023 Oct; 12(19):e030359. PubMed ID: 37776218
[TBL] [Abstract][Full Text] [Related]
7. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
[TBL] [Abstract][Full Text] [Related]
8. Long-term risk of atrial fibrillation or flutter after transcatheter patent foramen ovale closure: a nationwide Danish study.
Skibsted CV; Korsholm K; Pedersen L; Bonnesen K; Nielsen-Kudsk JE; Schmidt M
Eur Heart J; 2023 Sep; 44(36):3469-3477. PubMed ID: 37279491
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
[TBL] [Abstract][Full Text] [Related]
10. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
[TBL] [Abstract][Full Text] [Related]
12. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of Cryptogenic Stroke With Patent Foramen Ovale at Older Ages and Implications for Trials: A Population-Based Study and Systematic Review.
Mazzucco S; Li L; Rothwell PM
JAMA Neurol; 2020 Oct; 77(10):1279-1287. PubMed ID: 32628255
[TBL] [Abstract][Full Text] [Related]
14. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
[TBL] [Abstract][Full Text] [Related]
15. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
[TBL] [Abstract][Full Text] [Related]
16. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial.
Lee PH; Song JK; Kim JS; Heo R; Lee S; Kim DH; Song JM; Kang DH; Kwon SU; Kang DW; Lee D; Kwon HS; Yun SC; Sun BJ; Park JH; Lee JH; Jeong HS; Song HJ; Kim J; Park SJ
J Am Coll Cardiol; 2018 May; 71(20):2335-2342. PubMed ID: 29544871
[TBL] [Abstract][Full Text] [Related]
17. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
18. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
[TBL] [Abstract][Full Text] [Related]
19. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
[TBL] [Abstract][Full Text] [Related]
20. New-onset atrial fibrillation following percutaneous closure of patent foramen ovale: a systematic review and meta-analysis.
Oliva L; Huszti E; Barker M; Frankfurter C; Hall R; Horlick E; Abrahamyan L
J Interv Card Electrophysiol; 2021 Mar; 60(2):165-174. PubMed ID: 33420712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
